वैकल्पिक उत्पाद विश्लेषण
आपकी अनुमति से हम गोपनीयता-सीमित विश्लेषण का उपयोग करके समझते हैं कि कौन-सी शोध यात्राएँ उपयोगी हैं। हम विज्ञापन ट्रैकर या सत्र रिकॉर्डिंग नहीं चलाते। आप यह विकल्प प्राथमिकताओं में बदल सकते हैं। पढ़ें गोपनीयता नीति.
Cboe Global Markets, Inc.'s published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $28.3B | |
|---|---|---|
| P/E (forward) | 21.9x |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $3.49B | $3.96B | $3.77B | $4.09B | $4.71B | +7.8% |
| Gross profit | $1.48B | $1.74B | $1.92B | $2.07B | $2.43B | +13.3% |
| Operating income | $805.9M | $489.6M | $1.06B | $1.10B | $1.47B | +16.2% |
| Net income | $529.0M | $235.0M | $761.4M | $764.9M | $1.10B | +20.1% |
| EPS (diluted) | $4.92 | $2.19 | $7.13 | $7.21 | $10.42 | +20.6% |
| EBITDA | $971.5M | $659.7M | $1.27B | $1.27B | $1.74B | +15.7% |
| R&D | $0 | $0 | $0 | — | — | +12.8% |
| SG&A | $372.2M | $452.0M | $517.8M | $557.2M | $91.5M | -29.6% |
Recent company headlines from major financial publishers.
The Base case models Cboe's modal compounding path where exclusive proprietary index options sustain solid mid-single-digit consolidated revenue growth (scaling from 7.0% down to 4.5% across the forecast horizon). Operating margins normalize between 31.5% and 33.0% as corporate cost discipline ($838M-$853M guided operating expenses) absorbs elevated clearing capex of $98M-$108M. Synthesized intrinsic fair value is $306.41, offering 12.96% upside from the share price of $271.26 as of October 2, 2026.
In the Bull case, structural adoption of zero-day-to-expiry (0DTE) index options accelerates among retail and institutional market participants, driving sustained double-digit SPX and VIX contract volume growth. International expansion of Data Vantage subscriptions continues to generate rapid non-transaction revenue gains, while operational leverage and completed clearing capabilities expand operating margins toward peer medians. Fair value in this path reaches $398.31.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 6.8% | $319 | $347 | $382 | $428 | $492 |
| 7.3% | $291 | $313 | $340 | $374 | $419 |
| 7.8% | $268 | $285 | $306 | $333 | $366 |
| 8.3% | $248 | $263 | $280 | $300 | $326 |
| 8.8% | $232 | $244 | $258 | $274 | $294 |
Upcoming earnings date and setup when available.
हर महीने प्रकाशित शोध संस्करण की रेटिंग। रेटिंग विश्लेषण की तारीख की कीमत की तुलना उचित मूल्य से करती है; यह इस बात का रिकॉर्ड नहीं है कि आकलन सही निकला या नहीं।
| वर्ष | जन॰ | फ़र॰ | मार्च | अप्रैल | मई | जून | जुल॰ | अग॰ | सित॰ | अक्टू॰ | नव॰ | दिस॰ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
